We serve Chemical Name:2,3-Dimethylpyridine-N-oxide CAS:22710-07-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3-Dimethylpyridine-N-oxide
CAS.NO:22710-07-2
Synonyms:2,3-Dimethylpyridine N-oxide;2,3-DIFLUORO-4-BROMOPHENOL;2,3-dimethyl-pyridine-1-oxide;2,3-Dimethylpyridine 1-oxide;2,3-Lutidine 1-oxide;2,3-lutidine-N-oxide;2,3-DIMETHYL-4-PYRIDINE-N-OXIDE;5,6-dimethyl-3-pyridinyl-N-Oxide;3-methyl-2-picoline-N-oxide;MFCD00460842;Rabeprazole Impurity 8
Molecular Formula:C7H9NO
Molecular Weight:123.15200
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:298.1ºC at 760 mmHg
Density:1 g/cm3
Index of Refraction:1.509
PSA:25.46000
Exact Mass:123.06800
LogP:1.73190
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,3-Dimethylpyridine N-oxide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Rabeprazole Impurity 8 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-Dimethylpyridine 1-oxide Use and application,Rabeprazole Impurity 8 technical grade,usp/ep/jp grade.
Related News: The little-known Italian company making the glass vials for most of the globe’s Covid-19 vaccines just scored a rare feat: a New York Stock Exchange IPO. It’s the biggest public offering for an Italian firm in the U.S. since Ferrari’s 2015 listing. 2-[2-(2-hydroxy-naphthalen-1-ylazo)-phenyl]-3H-quinazolin-4-one manufacturers With the closing of AstraZeneca’s mega $39 billion buyout of Alexion Pharmaceuticals this week, the U.K. pharma has officially picked up Soliris and its successor, Ultomiris. N-Formyl-4-(1′-bromoethyl)-piperidine suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. syn 4a,10:9,9a-diepoxy-4a,9,9a,10-tetrahydroanthracene vendor & factory Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions.,With the closing of AstraZeneca’s mega $39 billion buyout of Alexion Pharmaceuticals this week, the U.K. pharma has officially picked up Soliris and its successor, Ultomiris.
